Alkermes
therapy has proven anti tumor efficacy is a natural regulator of the activity of lymphocytes involved in the immune response human as can drive complete and durable responses in certain tumor types but its toxicity profile significantly limits its potential application a molecule with differentiated tolerability that targets the pathway could be complementary to a wide range of other therapeutic approaches non specific agents specific agents cytotoxic chemotherapy first generation native scientific insight enabled by targeted agents engineered new molecule with engineered specificity | Alkermes
Company
Deck Type
Sector
Industry
Deck date
March 2021
Slide
57 of 144
Related slides by other companies
Immatics
Investor Presentation
November 2023
is where the data is | Immatics
Rigetti
SPAC
October 2021
enhance human health and longevity | Rigetti
Fusion Pharmaceuticals
Investor Presentation
November 2023
resurgence | Fusion Pharmaceuticals
DeepMind
Product
April 2023
building dialogue agents are all the rage at the moment we have our own powerful systems of course sparrow an information seeking dialogue agent designed to be more helpful correct and designed to answer questions with responses that are useful and evidence based safety is reinforcement learning from human feedback and a set of rules help reduce the risk of unsafe and inappropriate answers frontier fun engaging accurate safe improving alignment of dialogue agents via targeted human | DeepMind
Other recent decks by Alkermes
See all presentations (22 decks)
Investor Conference
January 2024
Results
October 2023
Investor Presentation
October 2023
Results
July 2023
Search Thousands of Presentations by World Leading Companies
Trending:
Addressable Market
Ecosystem
Beauty Market
WACC
NFT
Management Team
Investment Highlights

Stay in the loop

Join our mailing list to stay in the loop with updates and newest feature releases

Presentations

Start Up
IPO
SPAC
M&A
Investor Day
Results
ESG
Credit
Investment Banking

Explore

Presentation Collections
Slide Collections

Company

Blog
Contact us
© 2021-2023 Slidebook.io